<div id="readability-page-1"><p>Definitive Healthcare (NASDAQ:DH - Get Free Report) updated its first quarter 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 0.030-0.030 for the period, compared to the consensus estimate of 0.050. The company issued revenue guidance of $54.0 million-$56.0 million, compared to the consensus revenue estimate of $57.2 million. Definitive Healthcare also updated its FY 2026 guidance to 0.140-0.170 EPS.</p><div><p><span></span><span>Get <strong>Definitive Healthcare</strong> alerts:</span></p></div><h2>Definitive Healthcare Stock Performance</h2><p>Shares of NASDAQ DH traded down $0.01 during trading hours on Thursday, hitting $1.40. 753,013 shares of the company's stock were exchanged, compared to its average volume of 372,979. The company's 50-day moving average price is $2.23 and its 200-day moving average price is $2.90. Definitive Healthcare has a 1-year low of $1.36 and a 1-year high of $5.22. The stock has a market capitalization of $197.91 million, a price-to-earnings ratio of -0.84 and a beta of 1.59. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.60 and a quick ratio of 1.60. </p><p>Definitive Healthcare (NASDAQ:DH - Get Free Report) last released its earnings results on Thursday, February 26th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06. The firm had revenue of $61.53 million for the quarter, compared to analyst estimates of $59.57 million. Definitive Healthcare had a positive return on equity of 3.30% and a negative net margin of 77.88%.Definitive Healthcare has set its FY 2026 guidance at 0.140-0.170 EPS and its Q1 2026 guidance at 0.030-0.030 EPS.  On average, sell-side analysts expect that  Definitive Healthcare will post 0.16 earnings per share for the current fiscal year. </p><h2>Analysts Set New Price Targets</h2><p>A number of equities analysts recently issued reports on the stock. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Definitive Healthcare in a research report on Wednesday, January 21st. William Blair upgraded shares of Definitive Healthcare to a &#34;strong-buy&#34; rating in a research report on Thursday, November 6th. Wall Street Zen lowered shares of Definitive Healthcare from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a research report on Sunday, December 28th. Barclays reduced their target price on shares of Definitive Healthcare from $3.00 to $2.75 and set an &#34;underweight&#34; rating for the company in a research note on Monday, December 8th. Finally, Morgan Stanley  restated an &#34;underperform&#34; rating and set a $3.50 price target on shares of Definitive Healthcare in a research note on Thursday, December 18th. One equities research analyst  has rated the stock with a Strong Buy rating, one  has given a Buy rating, three have given a Hold rating and three have assigned  a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $3.94.</p><p><b>Check Out Our Latest Research Report on DH</b></p><h2>Institutional Inflows and Outflows</h2><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new stake in  Definitive Healthcare during the second quarter valued at approximately $32,000.  Schonfeld Strategic Advisors LLC bought a new position in shares of  Definitive Healthcare during the 4th quarter worth approximately $35,000.  Bayesian Capital Management LP bought a new position in shares of  Definitive Healthcare during the 2nd quarter worth approximately $55,000.  Prelude Capital Management LLC acquired a new stake in  Definitive Healthcare in the 3rd quarter valued at $64,000.  Finally, ExodusPoint Capital Management LP bought a new stake in  Definitive Healthcare in the fourth quarter valued at $47,000. Institutional investors own  98.67% of the company's stock. </p><h2>About Definitive Healthcare</h2> (Get Free Report)<p>Definitive Healthcare <span>NASDAQ: DH<span></span></span> is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.  </p><p>The company's flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.</p><h2>See Also</h2><ul><li>Five stocks we like better than Definitive Healthcare</li><li>Read this or regret it forever</li><li>Unlocked: Elon Musk’s Next Big IPO</li><li>This makes me furious</li><li>The &#34;Trump Effect&#34; on IRAs over $50k</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Definitive Healthcare Right Now?</h2><p>Before you consider Definitive Healthcare, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Definitive Healthcare wasn't on the list.</p><p>While Definitive Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Definitive Healthcare (NASDAQ:DH) has updated its Q1 2026 earnings guidance, projecting EPS of $0.030, below the consensus estimate of $0.050. Revenue guidance is set at $54.0-$56.0 million, also lower than the consensus of $57.2 million. The company has adjusted its FY 2026 EPS guidance to $0.140-$0.170. The stock traded down to $1.40, with a market cap of $197.91 million and a consensus rating of "Hold" from analysts.</p>

Definitive Healthcare (NASDAQ:DH) Releases Q1 2026 Earnings Guidance